Use of cookies by
Norton Rose Fulbright
We use cookies to deliver our online services. Details and instructions on how to disable those cookies are set out at nortonrosefulbright.com/cookies-policy. By continuing to use this website you agree to our use of our cookies unless you have disabled them.
Evolution of Canadian Intellectual Property Legislation Affecting Innovative Drug Products | Canada | Norton Rose Fulbright

Evolution of Canadian Intellectual Property Legislation Affecting Innovative Drug Products

January 2012

Contacts

Key industry sectors

The Norton Rose Canada LLP Guide to the "Evolution of Canadian Intellectual Property Legislation Affecting Innovative Drug Products" provides a brief historical survey of the legislative protection extended to innovative drug products in Canada, including a consideration of Canada's international treaty obligations respecting IP rights.

Download Evolution of Canadian Intellectual Property Legislation Affecting Innovative Drug Products (pdf 431kb)